EU Pilot Shows Single Drug Development Plan Can Meet Both Regulator And HTA Needs
This article was originally published in SRA
Executive Summary
The EU's pilot exercise in offering drug developers parallel regulatory and health technology assessment (HTA) advice has shown that in most cases a single trial design or drug development plan can be agreed that meets the requirements of the two parties without blurring their respective remits, says a new report from the European Medicines Agency1.
You may also be interested in...
Single Gateway For EMA-HTA Advice May Answer All Stakeholders’ Needs
The EU research-based pharmaceutical industry has welcomed the launch of a new single gateway for companies to seek parallel scientific advice from the European Medicines Agency and health technology assessment bodies on initial evidence generation and post-authorization data collection. The industry hopes the initiative will help deliver one single evidence package for regulatory and HTA purposes.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.